- The P-III DELOS trial involves assessing of idebenone (900mg/day) vs PBO in 64 patients with DML for 52 wks.
- P-III DELOS study results: 50% reduction in annual rates of forced vital capacity; treatment effect remained 6 yrs.; reduction in risk of important patient-relevant outcomes including bronchopulmonary AEs and hospitalizations; reductions in the rate of both inspiratory and expiratory respiratory function loss
- Idebenone is a benzoquinone and a cofactor for the enzyme NAD(P)H H quinone oxidoreductase (NQO1) approved for Leber’s hereditary optic neuropathy (LHON) in the EU including n, Norway, Iceland, Liechtenstein, Israel and Serbia
Click here to read full press release/ article | Ref: Santhera Pharmaceuticals | Image: Twitter